Proteomic analysis for developing new biomarkers of hepatocellular carcinoma

Table 1 Demographical and clinical data of the patients

n = 40	n (%)	Mean/median	SD/range
Gender
Male	29 (72.5)
Female	11 (27.5)
Age		55.6	9.5
Etiology of cirrhosis
HBV	10 (25)
HCV	16 (40)
ALD	14 (35)
Child-Pugh		5.5	(5-10)

SD: Standard deviation; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ALD: Alcoholic liver disease; HCC: Hepatocellular carcinoma.

Table 2 Comparison of demographic and clinical data between patients with and without HCC

	NO HCC	HCC	P
Male	72.70%	72.20%	0.97
Age (yrs)	54.6 ± 10.1	56.8 ± 8.7	0.46
Etiology of cirrhosis
HBV	22.70%	27.80%	0.69
HCV	36.40%	44.40%	0.69
ALD	40.90%	27.80%	0.69
Child-Pugh	10 ± 3.2	5.6 ± 0.9	0.01
HBV-DNA	81.2 ± 94.8	146 ± 206.4	0.56
HCV viral load	1.8 × 106± 2.9 × 106	6.1 × 106± 4.2 × 106	0.28
ALT	53.9 ± 66.1	83.5 ± 95.7	0.39
AST	86.7 ± 111.1	92.2 ± 80.6	0.89
Bilirubin	3.4 ± 2.9	3.1 ± 3.6	0.81
GGT	69.5 ± 38.8	156.1 ± 159.6	0.09
AP	156 ± 74.5	101.2 ± 40.5	0.05
Albumin	3.3 ± 0.7	3.3 ± 0.4	0.99
INR	1.4 ± 0.3	1.2 ± 0.1	0.04
Creatinine	1.7 ± 2.1	1.1 ± 0.3	0.28
LDH	414 ± 52.7	399 ± 52.3	0.97
AFP	14.7 ± 15.8	698.4 ± 1391.1	0.13

ALT: Alanine transaminase; AST: Aspartate transaminase; GGT: Gamma glutamyl transpeptidase; INR: International normalized ratio; AP: Alkaline phosphatase; LDH: Lactate dehydrogenase; AFP: Alfa-fetoprotein.